N/A
|
MGCD-265 analog（Cat No.:I005271）is a multi-targeted kinase inhibitor designed to block key receptors such as MET, VEGFR, and AXL, which are involved in tumor growth, angiogenesis, and metastasis. By inhibiting these pathways, MGCD-265 analog disrupts cancer
|
Buy from Supplier |
N/A
|
MGCD-265 analog is a potent and oral active inhibitor of c-Met and VEGFR2 tyrosine kinases, with IC50s of 29 nM and 10 nM, respectively. MGCD-265 analog has significant antitumor activity.
|
Buy from Supplier |
93
|
Selleck Chemicals
mgcd 265 Mgcd 265, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/mgcd/MGCD-265+analog/pmc06338618-202-11-25 Average 93 stars, based on 1 article reviews
mgcd 265 - by Bioz Stars,
2026-10
93/100 stars
|
Buy from Supplier |
90
|
ChemieTek LLC
mgcd-0103 Mgcd 0103, supplied by ChemieTek LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/mgcd/mgcd+0103/pmc05717743-450-28-30 Average 90 stars, based on 1 article reviews
mgcd-0103 - by Bioz Stars,
2026-10
90/100 stars
|
Buy from Supplier |
90
|
MultiTarget Pharmaceuticals
sitravatinib (mgcd-156)  Sitravatinib (Mgcd 156), supplied by MultiTarget Pharmaceuticals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/mgcd/sitravatinib++mgcd+156+/pmc08038660-356-0-4 Average 90 stars, based on 1 article reviews
sitravatinib (mgcd-156) - by Bioz Stars,
2026-10
90/100 stars
|
Buy from Supplier |
90
|
MethylGene Inc
mgcd-1030 Mgcd 1030, supplied by MethylGene Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/mgcd/mgcd+1030/pm23506149-352-0-3 Average 90 stars, based on 1 article reviews
mgcd-1030 - by Bioz Stars,
2026-10
90/100 stars
|
Buy from Supplier |
N/A
|
InformationMGCD-265 is a potent, multi-target and ATP-competitive inhibitor ofc-MetandVEGFR1/2/3withIC50of 1 nM, 3 nM/3 nM/4 nM, respectively; also inhibits Ron and Tie2. Phase 1/2.In vitroMGCD-265 is a multi-target inhibitor of receptor tyrosine kinases. MGCD-265 potently inhibits
|
Buy from Supplier |
N/A
|
MGCD-265 is a potent, multi-target, and ATP-competitive receptor tyrosine kinase inhibitor of Met, Flt-1, Flt-4, Flk-1, Ron, and Tie-2 (IC50 = 1 nM - 7 nM).
|
Buy from Supplier |
N/A
|
Application：MGCD-265 analog is a potent and oral active inhibitor of c-Met and VEGFR2 tyrosine kinases, with IC50s of 29 nM and 10 nM, respectively. MGCD-265 analog has significant antitumor activity
|
Buy from Supplier |
N/A
|
MGCD-265 is a potent, multi-target and ATP-competitive inhibitor of c-Met and VEGFR1/2/3 with IC50 of 1 nM, 3 nM/3 nM/4 nM, respectively and also inhibits Ron and Tie2.
|
Buy from Supplier |
Image Search Results
Journal: Cancers
Article Title: The Yin and Yang of Discoidin Domain Receptors (DDRs): Implications in Tumor Growth and Metastasis Development
doi: 10.3390/cancers13071725
Figure Lengend Snippet: Nonspecific DDR inhibitors: specificities and clinical trials (adapted from ClinicalTrials.gov ).
Article Snippet:
Techniques: Clinical Proteomics, In Vitro, Phospho-proteomics, Migration, Biomarker Discovery